Amphastar Pharmaceuticals (AMPH) Depreciation and Depletion (2013 - 2026)

Amphastar Pharmaceuticals' Depreciation and Depletion history runs 14 years deep, the most recent figure standing at $8.1 million for Q1 2026.

• In Q1 2026, Depreciation and Depletion rose 9.62% year-over-year to $8.1 million; the TTM figure through Mar 2026 stood at $32.3 million (up 12.18% YoY), while the FY2025 annual figure was $31.6 million, up 11.86% from the prior year.
• Depreciation and Depletion was $8.1 million for Q1 2026 at Amphastar Pharmaceuticals, up from $8.0 million in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $8.3 million in Q2 2025 to a low of $5.6 million in Q1 2022.
• Historically, Depreciation and Depletion has averaged $6.9 million across 5 years, with a median of $6.8 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Depreciation and Depletion retreated 1.25% in 2022, then climbed 20.01% in 2025.
• A 5-year view of Depreciation and Depletion shows it stood at $6.2 million in 2022, then climbed by 7.11% to $6.6 million in 2023, then rose by 9.28% to $7.3 million in 2024, then grew by 10.57% to $8.0 million in 2025, then climbed by 0.67% to $8.1 million in 2026.
• The last three Depreciation and Depletion figures came in at $8.1 million (Q1 2026), $8.0 million (Q4 2025), and $7.9 million (Q3 2025), per Business Quant data.